IP Library Granted Patent US 7,176,240
Granted Patent B2
US 7,176,240 · App. 10/194,247 · Granted Feb 13, 2007

Pentanoic acid derivatives

Assignee: Ono Pharmaceutical Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,176,240
App. No.
10/194,247
Granted
Feb 13, 2007
Kind
B2
Abstract

The compound of the formula (I): wherein R 1 is alkyl substituted by fluorine(s); R 2 is hydroxy, alkoxy, alkoxy substituted by phenyl, NR 3 R 4 , in which R 3 , R 4 is (i) hydrogen, (ii) alkyl, (iii) phenyl, (iv) phenyl substituted by alkoxy or carboxyl, (v) heterocyclic ring containing nitrogen atom, (vi) alkyl substituted by phenyl, phenyl substituted by alkoxy or carboxyl, heterocyclic ring containing nitrogen atom, (vii) the nitrogen bonded to R 3 and R 4 , taken together a saturated heterocyclic ring or amino acid residues; and non-toxic salts thereof and acid addition salts thereof. The compounds of the present invention of the formula (I) and the compounds of the formula (X): wherein n is 0 or 1, R 11 is hydrogen and chlorine, R 5 is R 7 —CH 2 — or R 8 , or R 5 and R 11 , taken together is alkylidene; R 6 is hydroxy, alkoxy, alkoxy substituted by phenyl, NR 9 R 10 , in which R 9 , R 10 is (i) hydrogen, (ii) alkyl, (iii) phenyl, (iv) phenyl substituted by alkoxy or carboxyl, (v) heterocyclic ring containing nitrogen atom, (vi) alkyl substituted by phenyl, phenyl-substituted by alkoxy or carboxyl, heterocyclic ring containing nitrogen atom, (vii) the nitrogen bonded to R 9 and R 10 , taken together a saturated heterocyclic ring or amino acid residues, R 7 is (i) F—(CH 2 ) m — or F 3 C—CH 2 —, (ii) alkyl substituted by chlorine, (iii) alkyl substituted by alkoxy, cycloalkyl, phenyl, phenoxy; R 8 is alkyl, alkenyl, alkoxy, alkylthio, cycloalkyl, phenyl, phenoxy; non-toxic salts and acid addition salts thereof are useful for prevention and/or treatment for neurodegenerarive disease (Alzheimer's disease etc.) and neuronal dysfunction by stroke or traumic injury (Multiple sclerosis etc.) etc.

Claims (43)

1. A compound of the formula (I):

wherein R 1 is C1–10 alkyl having one carbon substituted by 1–3 fluorines;

R 2 is hydroxy, C1–4 alkoxy, C1–4 alkoxy substituted by 1 of phenyl, or NR 3 R 4 , in which R 3 and R 4 each, independently, is

(i) hydrogen,

(ii) C1–4 alkyl,

(iii) phenyl,

(iv) phenyl substituted by C1–4 alkoxy or carboxyl,

(v) 4–7 membered heterocyclic ring containing one nitrogen or

(vi) C1–4 alkyl substituted by phenyl, phenyl substituted by C1–4 alkoxy or carboxyl, or 4–7 membered heterocyclic ring containing one nitrogen, or the nitrogen atom bonded to them, taken together is 4–7 membered saturated heterocyclic ring containing one or two nitrogen(s) or one nitrogen and one oxygen, or amino acid residue;

with the proviso that, R 1 is not F—(CH 2 ) 4 —, F—(CH 2 ) 5 —, F—(CH 2 ) 6 —, F 3 C—CH 2 —,

or non-toxic salts thereof or acid addition salts thereof.

2. A compound according to claim 1 , wherein R 1 is C1–7 alkyl having one carbon substituted by 1–3 of fluorines.

3. A compound according to claim 1 , wherein R 2 is hydroxy, C1–4 alkoxy, C1–4 alkoxy substituted by 1 of phenyl.

4. A compound according to claim 1 , wherein R 2 is NR 3 R 4 , in which R 3 and R 4 each, independently, is

(i) hydrogen,

(ii) C1–4 alkyl,

(iii) phenyl,

(iv) phenyl substituted by C1–4 alkoxy or carboxyl,

(v) 4–7 membered heterocyclic ring containing one nitrogen or

(vi) C1–4 alkyl substituted by phenyl, phenyl substituted by C1–4 alkoxy or carboxyl, or 4–7 membered heterocyclic ring containing one nitrogen.

5. A compound according to claim 1 , wherein R 2 is NR 3 R 4 , in which R 3 , R 4 and the nitrogen atom bonded to them, taken together is 4–7 membered saturated heterocyclic ring containing one or two nitrogens or one nitrogen and one oxygen, or amino acid residue.

6. A compound according to claim 1 , which is

5-fluoro-2-propylpentanoic acid,

6-fluoro-2-propylhexanoic acid,

5,5-difluoro-2-propylpentanoic acid,

7,7-difluoro-2-propylheptanoic acid,

8,8-difluoro-2-propyloctanoic acid,

6,6-difluoro-2-propylhexanoic acid,

9,9-difluoro-2-propylnonanoic acid,

6,6,6-trifluoro-2-propylhexanoic acid,

8,8,8-trifluoro-2-propyloctanoic acid,

7,7,7-trifluoro-2-propylheptanoic acid,

9,9,9-trifluoro-2-propylnonanoic acid,

4,4,4-trifluoro-2-propylbutanoic acid,

2-phenylethyl 6,6,6-trifluoro-2-propylhexanoate.

7. A compound according to claim 1 , which is

6,6,6-trifluoro-2-propyl-N-(4-methoxyphenyl)hexanamide,

6,6,6-trifluoro-2-propyl-N-benzylhexanamide,

6,6,6-trifluoro-2-propyl-N-(3-pyridyl)hexanamide,

6,6,6-trifluoro-2-propyl-N-(3-carboxyphenyl)hexanamide.

8. A compound according to claim 1 , which is

N-(1-carboxyethyl)-6,6,6-trifluoro-2-propylhexamide.

9. A pharmaceutical composition which comprises, as active ingredient, an effective amount of a pentanoic acid derivative of the formula (I) depicted in claim 1 or non-toxic salts thereof or acid addition salts thereof with a pharmaceutical carrier or coating.

Priority Claims (3)
JP 5-154331 · Jun 1, 1993 · national
JP 5-301067 · Nov 5, 1993 · national
JP 6-80982 · Mar 28, 1994 · national
Continuity (4)
Continuation 0966105400 · Sep 13, 2000
Division 0868148200 · Jul 23, 1996
Continuation 0825264200 · Jun 1, 1994
Related Publication 20030096802A1 · May 22, 2003